Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ·Healthcare·Biotechnology
$40.95
+0.00%
Mkt Cap $5.23B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 24, 2026 | $199.39M | $199.91M | +0.26% | -$0.39 | -$0.47 | -20.51% | — | — |
| Q4 2025 Oct 30, 2025 | $199.28M | $458.58M | +130.12% | $1.03 | $1.67 | +62.14% | — | — |
| Q3 2025 Jul 31, 2025 | $371.95M | $178.49M | -52.01% | -$0.44 | -$0.33 | +25.00% | — | — |
| Q2 2025 May 7, 2025 | $209.24M | $166.80M | -20.29% | -$0.36 | -$0.74 | -105.56% | — | — |
| Q1 2025 Feb 28, 2025 | $199.11M | $212.53M | +6.74% | -$0.37 | -$0.29 | +21.62% | — | — |
| Q4 2024 Nov 5, 2024 | $191.93M | $196.83M | +2.56% | -$0.32 | -$0.46 | -43.75% | — | — |
| Q3 2024 Aug 1, 2024 | $191.07M | $199.69M | +4.51% | -$0.33 | -$0.28 | +15.15% | — | — |
| Q2 2024 May 7, 2024 | $163.35M | $172.32M | +5.49% | -$0.54 | -$0.54 | +0.00% | — | — |
| Q1 2024 Feb 27, 2024 | $143.59M | $146.38M | +1.94% | -$0.66 | -$0.73 | -10.61% | — | — |
| Q4 2023 Nov 1, 2023 | $99.74M | $99.18M | -0.56% | -$0.84 | -$1.17 | -39.29% | — | — |
| Q3 2023 Jul 31, 2023 | $81.12M | $94.97M | +17.07% | -$1.35 | -$1.02 | +24.44% | — | — |
| Q2 2023 May 4, 2023 | $26.10M | $44.85M | +71.82% | -$1.42 | -$1.56 | -9.86% | — | — |
| Q1 2023 Feb 21, 2023 | $24.41M | $22.66M | -7.16% | -$1.65 | -$1.50 | +9.09% | — | — |
| Q4 2022 Nov 7, 2022 | $21.59M | $22.06M | +2.15% | -$1.48 | -$1.75 | -18.24% | — | — |
| Q3 2022 Aug 8, 2022 | $16.95M | $16.32M | -3.68% | -$1.43 | -$1.46 | -2.10% | — | — |
| Q2 2022 May 4, 2022 | $12.57M | $14.38M | +14.38% | -$1.36 | -$1.42 | -4.41% | — | — |
| Q1 2022 Feb 28, 2022 | $8.79M | $60.29M | +586.19% | -$1.32 | -$1.61 | -21.97% | — | — |
| Q4 2021 Nov 8, 2021 | $13.98M | $5.65M | -59.59% | -$1.73 | -$2.28 | -31.79% | — | — |
| Q3 2021 Aug 9, 2021 | $623.00K | $623.00K | +0.00% | -$1.70 | -$2.72 | -60.00% | — | — |
| Q2 2021 Apr 28, 2021 | $2.50M | — | — | -$1.69 | -$2.32 | -37.28% | — | — |